BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chowdhury EA, Meno-Tetang G, Chang HY, Wu S, Huang HW, Jamier T, Chandran J, Shah DK. Current progress and limitations of AAV mediated delivery of protein therapeutic genes and the importance of developing quantitative pharmacokinetic/pharmacodynamic (PK/PD) models. Adv Drug Deliv Rev 2021;170:214-37. [PMID: 33486008 DOI: 10.1016/j.addr.2021.01.017] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Burr A, Erickson P, Bento R, Shama K, Roth C, Parekkadan B. Allometric-like scaling of AAV gene therapy for systemic protein delivery. Molecular Therapy - Methods & Clinical Development 2022;27:368-379. [DOI: 10.1016/j.omtm.2022.10.011] [Reference Citation Analysis]
2 Kim S, Przybilla MJ, Whitley CB, Ou L, Al-Kofahi M, Jarnes JR. Identification of a novel fusion Iduronidase with improved activity in the cardiovascular system. Mol Genet Metab Rep 2022;33:100917. [PMID: 36159322 DOI: 10.1016/j.ymgmr.2022.100917] [Reference Citation Analysis]
3 Rose RH, Sepp A, Stader F, Gill KL, Liu C, Gardner I. Application of physiologically-based pharmacokinetic models for therapeutic proteins and other novel modalities. Xenobiotica 2022;:1-27. [PMID: 36214113 DOI: 10.1080/00498254.2022.2133649] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Zhang J, Zhang T, Gao J. Biocompatible Iron Oxide Nanoparticles for Targeted Cancer Gene Therapy: A Review. Nanomaterials 2022;12:3323. [DOI: 10.3390/nano12193323] [Reference Citation Analysis]
5 Moffit JS, Blanset DL, Lynch JL, MacLachlan TK, Meyer KE, Ponce R, Whiteley L. Regulatory Consideration for the Nonclinical Safety Assessment of Gene Therapies. Hum Gene Ther 2022. [PMID: 35994386 DOI: 10.1089/hum.2022.090] [Reference Citation Analysis]
6 Chandran J, Chowdhury EA, Perkinton M, Jamier T, Sutton D, Wu S, Dobson C, Shah DK, Chessell I, Meno-tetang GML. Assessment of AAV9 distribution and transduction in rats after administration through Intrastriatal, Intracisterna magna and Lumbar Intrathecal routes. Gene Ther. [DOI: 10.1038/s41434-022-00346-1] [Reference Citation Analysis]
7 Hou L, Kumar M, Anand P, Chen Y, El-bizri N, Pickens CJ, Seganish WM, Sadayappan S, Swaminath G. Modulation of myosin by cardiac myosin binding protein-C peptides improves cardiac contractility in ex-vivo experimental heart failure models. Sci Rep 2022;12. [DOI: 10.1038/s41598-022-08169-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Wu H, Hu D, Li Q, Wang C, Zhu X, Li W, Chen B, Ji P, Huang K, Huang A, Huang J, Dimitrov DS, Wu Y, Ying T. Half-life extension enhances drug efficacy in adeno-associated virus delivered gene therapy. Engineering 2022. [DOI: 10.1016/j.eng.2022.02.009] [Reference Citation Analysis]
9 Chen N, Sun K, Chemuturi NV, Cho H, Xia CQ. The Perspective of DMPK on Recombinant Adeno-Associated Virus-Based Gene Therapy: Past Learning, Current Support, and Future Contribution. AAPS J 2022;24:31. [PMID: 35102450 DOI: 10.1208/s12248-021-00678-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
10 Hoad M, Roby JA, Forwood JK. Structural characterization of the porcine adeno-associated virus Po1 capsid protein binding to the nuclear trafficking protein importin alpha. FEBS Lett 2021;595:2793-804. [PMID: 34661283 DOI: 10.1002/1873-3468.14209] [Reference Citation Analysis]
11 Aksenov S, Roberts JC, Mugundu G, Mueller KT, Bhattacharya I, Tortorici MA. Current and Next Steps Toward Prediction of Human Dose for Gene Therapy Using Translational Dose-Response Studies. Clin Pharmacol Ther 2021. [PMID: 34365642 DOI: 10.1002/cpt.2374] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
12 Tang Y, Cao Y. Modeling Pharmacokinetics and Pharmacodynamics of Therapeutic Antibodies: Progress, Challenges, and Future Directions. Pharmaceutics 2021;13:422. [PMID: 33800976 DOI: 10.3390/pharmaceutics13030422] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
13 McIntosh A, Sverdlov O, Yu L, Kaufmann P. Clinical Design and Analysis Strategies for the Development of Gene Therapies: Considerations for Quantitative Drug Development in the Age of Genetic Medicine. Clin Pharmacol Ther 2021;110:1207-15. [PMID: 33666225 DOI: 10.1002/cpt.2224] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]